Muhammad Aqib Faizan: The Role of Novel Anticoagulants Factor XI/XIa Inhibitors in the Atrial Fibrillation Population
Muhammad Aqib Faizan, Clinical Intern at District Headquarter Hospital, MTI, DIKhan, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”New study
I had the privilege of leading this study regarding the role of novel anticoagulants FactorXI/XIa inhibitors in atrial fibrillation population (high-thromboembolic-risk patients (mean CHA2DS2-VASc scores 3.9-5.0).
The findings offer a compelling trade-off.
- Significantly lower risk of bleeding across all doses
- Fourfold rise in ischemic stroke
- No significant difference in cardiovascular death, all-cause mortality, or major adverse events indicates general tolerance and neutrality in survival outcomes.
This profile may offer a lifeline for high-risk patients-those in whom bleeding concerns limit traditional anticoagulation.
But the fourfold increase in ischemic stroke is a critical signal.
Proud of what this team accomplished. Huge thanks to Tooba Rehman, Zeyad Kholeif, Fatima Saeed, Jibran Ikram, Alina Tanvir, Carlos Alberto E., Saad Ahmed Waqas, and our mentor, Luis Cerna, whose insights made this happen.”
Title: Dose-Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta-Analysis With Subgroup Exploration and Trial Sequential Validation
Authors: Muhammad Aqib Faizan, Tooba Rehman, Mrunalini Dandamudi, Jaivardhan A. Menon, Victoria Zecchin Ferrara, Zeyad Kholeif, Alina Tanvir, Fatima Saeed, Jibran Ikram, Moiuz Chaudhri, Carlos Espiche, Main Muhammad Salman Aslam, Zainab Humayun, Ahmad Mustafa Khalid, Saad Ahmad Waqas, Raheel Ahmad, Luis Cerna
Read the Full Article on Clinical Cardiology.

Stay updated with Hemostasis Today.
-
Oct 4, 2026, 06:12David McIntosh: 900 Plasma Donations One Patient One Lifeline
-
Oct 4, 2026, 06:00Aadil Sheikh: Menopausal Hormone Therapy and Thrombosis Rethinking Route Dose and Risk
-
Oct 4, 2026, 05:39Alicja Urbaniak: Targeting CD148 for Novel Antithrombotic Therapy
-
Oct 4, 2026, 05:27Nirali Thakkar: Influenza and Myocardial Infarction An Unexpected Cardiovascular Connection
-
Oct 4, 2026, 05:03Hisham Fahmi: Thromboprophylaxis in Children With ALL A Risk Adapted Approach
-
Oct 4, 2026, 05:00Mary Cushman: Erin Michos Highlights Rising Heart Disease Mortality Among Younger Women in the US
-
Oct 4, 2026, 04:48Liv Tybjærg Nordestgaard: Is Fasting Necessary Before Blood Sampling?
-
Oct 4, 2026, 04:31Sonal Sonu: Gen Z doesn’t just set trends – Gen Z saves lives
-
Oct 4, 2026, 04:22Registration Opens for 2027 Highlights of ASH – American Society of Hematology